Menzaghi Frederique Ph.D.

SEC source: 0001415889-24-002515 · form4-02052024_090257.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · CHIEF SCIENTIFIC OFF,SVP-R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,247

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.

SEC source: 0001209191-23-039883 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,747

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 5, 2018 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-23-023605 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,740

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 to $4.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-23-016795 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,473

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-23-015562 · doc4.xml · derivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2023, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-062632 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,275

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on December 21, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-22-023241 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,781

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on April 1, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-22-013986 · doc4.xml · derivative · entry 3

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-02-25

F3 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-013986 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,565

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-22-013986 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,679

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-070816 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,679

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-21-054302 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,072

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-053535 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,919

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of two possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-024298 · doc4.xml · derivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2031-03-30

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30, 2021, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-21-024298 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,319

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-018656 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,319

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-018656 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,677

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-014549 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,677

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-014549 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,680

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award.

SEC source: 0001209191-20-065581 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,680

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person.

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1).

SEC source: 0001209191-20-065409 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,492

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-025307 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,492

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.

F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5569 to $15.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-20-025307 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,386

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on April 17, 2020. The vested shares represent the total number of remaining shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-20-013098 · doc4.xml · derivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2030-02-24

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 24, 2020, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-20-013098 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,886

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 24, 2021, February 24, 2022 and February 24, 2023, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-19-054364 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.825 to $19.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-053798 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.20 to $19.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-053312 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $18.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-052768 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-048602 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.69 to $23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-044643 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

SEC source: 0001209191-19-042806 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-041022 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,882

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.74 to $22.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-033516 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,882

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.

F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0001209191-19-033516 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,279

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on May 28, 2019. The vested shares represent one-half of the total number of shares subject to the award, and the remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-19-019509 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,779

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.21 to $19.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-019509 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,582

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $17.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-018222 · doc4.xml · derivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2029-03-06

F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-19-015839 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,779

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

SEC source: 0001209191-19-014161 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,279

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $17.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-19-000406 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,479

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person.

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001209191-18-064404 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,779

F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-18-061253 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.3001 to $18.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-057307 · doc4.xml · derivative · entry 3

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2020-10-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-18-057307 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.62 to $18.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-057307 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-053764 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.90 to $24.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-049921 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.581 to $20.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-048017 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,000

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001209191-18-057306 · doc4.xml · derivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2018-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Immediately exercisable.